MedTrace Logo

Seroprevalence of Infection-induced SARS-CoV-2 Antibodies (COVID-19) in Children

NCT05358626 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4032

Last updated 2023-03-09

No results posted yet for this study

Summary

It is unknown what proportion of children have been exposed to SARS-CoV-2 and how many have antibodies among children seeking medical care for non-Covid-19 related conditions.

The aim of this study is to identify children with IgG antibodies to SARS-CoV-2 who have not been previously diagnosed and are presumed/confirmed Covid-19 negative, then determine the level of immunity in this population which could inform further decisions about covid-19 vaccine strategies for children

Conditions

Interventions

DIAGNOSTIC_TEST

SARS-CoV-2 IgG Antibody testing

IgG Antibody testing for previous exposure to SARS-CoV-2

Sponsors & Collaborators

  • National Children's Hospital, Vietnam

    lead OTHER

Principal Investigators

  • Phuc H Phan, MD · Vietnam National Children's Hospital

Eligibility

Min Age
0 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-13
Primary Completion
2022-06-05
Completion
2022-11-13

Countries

  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05358626 on ClinicalTrials.gov